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ABSTRACT 
 
The inducible prostaglandin (PG) E2 pathway is defined by the concerted activities of 
the enzymes cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase 
(mPGES)-1 in producing PGE2. PGE2 has pro-inflammatory and immunomodulatory 
functions and is involved in an array of diseases with an autoimmune and chronic 
inflammatory component, including rheumatoid arthritis (RA). In RA, mPGES-1 and 
COX-2 are up-regulated in the inflamed synovium of patients. COX inhibitors like 
non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors 
(COXibs) relieve inflammation and pain in RA, but their respective GI tract and 
cardiovascular side effects preclude long-term use. Moreover, other effective RA 
therapies like TNF blockade and B-cell depletion therapy leave the inducible PGE2 
pathway unaffected, suggesting that targeting this pathway could have additional 
benefits in a combinatorial approach. mPGES-1 is currently investigated as a target that 
could dissociate the anti-inflammatory benefits of COX inhibitors from their 
detrimental side effects. However, most inhibitors of human mPGES-1 activity 
generated so far failed to inhibit the murine enzyme ortholog, which complicates their 
characterization in vivo in relevant disease models. 
 
The first objective of this thesis was to extend the characterization of the PGE2 
pathway in arthritis. The second objective was to investigate mPGES-1 as a therapeutic 
target. The latter was accomplished in part through the development and evaluation of 
pharmacological inhibitors active on both human and murine mPGES-1. 
 
To fulfill the first objective, we characterized a new mechanism for the induction of 
PGE2 production in RA synovial fibroblasts (RASFs), whereby complexes of the 
alarmin high mobility group box protein-1 (HMGB1) and the cytokine IL-1β cause an 
up-regulation of COX-2 and mPGES-1 expression. We also characterized 15-
prostaglandin dehydrogenase (15-PGDH) to co-localize with mPGES-1 and the COX 
enzymes in the synovium of RA patients, suggesting a concerted activity of the anabolic 
and catabolic parts of the PGE2 cascade in the joint. In the same patients, we 
determined that methotrexate therapy did not interfere with the expression of COXs, 
mPGES-1 or 15-PGDH, adding that therapy to the list of approaches leaving the PGE2 
pathway unaffected. Lastly, we could not confirm an association between the 
expression of COXs, mPGES-1 and 15-PGDH and quantitative pain assessment or 
arthritis development in arthralgic individuals at risk of developing arthritis or in early 
arthritis patients. In line with the second objective, we developed compounds II and 
III, which inhibit PGE2 synthesis in vitro in different human and murine cell assays and 
in vivo in the air pouch model of acute inflammation. Compound II also reduced edema 
in the rat adjuvant-induced arthritis (AIA) model. When the PG profile elicited by 
mPGES-1 inhibition with compound III was compared to that resulting from mPGES-
1 gene deletion in the air pouch model, different results were observed suggesting the 
two modes of inhibition might not have the exact same outcome. While inhibition of 
PGE2 synthesis with both compound II and III did not result in the shunting of PGH2 
to other prostanoids, a shunt to thromboxane (TX) B2 was observed in the mPGES-1 
knockout mouse. We also used the mPGES-1 knockout mouse to investigate the 
impact of mPGES-1 gene deletion on the eicosanoid and fatty acid profiles in 
inflammation. We discovered that it resulted in macrophages producing more 15-
	  	   	  
deoxy-Δ 12,14 PGJ2 and the spleen containing more eicosadienoic acid (EDA). This 
suggests mPGES-1 inhibition could not only inhibit the synthesis of the pro-
inflammatory PGE2, but also cause the up-regulation of anti-inflammatory pathways.  
 
In conclusion, this thesis further advances the knowledge about the PGE2 synthesis 
cascade in arthritis and describes two new mPGES-1 inhibitors with an in vivo activity in 
native rodent models of disease. The latter constitute new valuable tools for the study 
of mPGES-1 in whichever pathology it has an involvement. 
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THESIS AIMS 
 
The work presented in this thesis focused on extending the characterization of the 
PGE2 pathway in arthritis and on further validating mPGES-1 as a therapeutic target by 
developing pharmacological inhibitors of its enzymatic activity and by studying the 
mPGES-1 knockout mouse. 
 
 
Specific aims: 
 
Paper I  To investigate the involvement of the PGE2 pathway in the pre- 
  clinical and early clinical phases of arthritis.     
 
Paper II To characterize a new mechanism for the induction of PGE2   
  production in rheumatoid arthritis synovial fibroblasts 
 
Paper III To characterize the expression of 15-PGDH in the RA   
  synovium and study the impact of methotrexate treatment on  
  the expression of the inducible PGE2 pathway in RA. 
 
Paper IV To characterize a new pharmacological inhibitor of mPGES-1 in  
  vitro and in vivo in rat models of inflammation 
 
Paper V To characterize a new pharmacological inhibitor of mPGES-1 and  
  compare its effect to mPGES-1 gene deletion in vivo 
 
Paper VI To determine the impact of mPGES-1 gene deletion on the fatty acid 
  and eicosanoid profiles of mice 
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1 INTRODUCTION TO INFLAMMATION AND THE IMMUNE 
SYSTEM 
 
 
1.1 PHYSIOLOGICAL BARRIERS AND SURVEILLANCE 
 
At first glance, the human body surface might be perceived as an armor with several 
openings, but every surface and every cavity of it is coated with a barrier, either physical 
or chemical, that protects the tissue beneath from the outside environment and helps it 
to remain under homeostasis. In the event of an injury or a barrier breach, the body is 
equipped with a danger-sensing mechanism, which is managed by immune sentinel cells 
populating most tissues. These cells are equipped with receptors that recognize danger-
associated molecular patterns (DAMPs). DAMPs can be endogenous or exogenous in 
nature and one of them, HMGB1, will be the subject of section 2.1.1. Once induced, 
this mechanism causes the initiation of the inflammatory and immune reactions which, 
together, attempt to fight a given noxious condition to allow a return to homeostasis.  
 
 
1.2 INFLAMMATION 
 
Classically, inflammation has been described using the cardinal signs of inflammation: 
pain, heat, redness and swelling. Pain serves to alert the host of the abnormal state of an 
affected tissue. Heat, redness and swelling are caused by the increased blood flow and 
plasma leakage. When amplified, these cardinal signs inevitably lead to loss of function 
of the affected area. 
 
A more practical definition to help conceptualize inflammation would be that it is a 
physiological response with the purpose to create a suitable environment for invading 
organisms to be fought and damaged tissue to be repaired. More specifically, 
inflammation coordinates the delivery of blood components (i.e. immune system cells 
and the tissue repair machinery) to a location requesting it. Both cells of the afflicted 
organ and cells of the immune system orchestrate the inflammatory reaction. Most 
importantly, they communicate with each other via a complex regulatory network of 
mediators. These mediators include cytokines, chemokines, lipid mediators, vasoactive 
peptides and amines, complement fragments and proteolytic enzymes [1]. The cross 
talk between cells involved, essentially mediates their differentiation and modulates 
their activities. It also contributes to the recruitment of additional effector cells of the 
immune system. An important family of mediators that is part of this network is the 
prostanoid family. Prostanoids modulate all the cardinal signs of inflammation and are 
presented in section 2.2 and in figure 1. 
 
Under normal circumstances, inflammation is programmed to resolve when an injury 
has been repaired and/or a pathogen has been cleared by the immune system. 
However, in the event of a persistent infection or in cases of autoimmunity, the 
complex regulatory network of mediators previously mentioned can turn into a self-
perpetuating loop that drives inflammation to chronicity. Chronic inflammation is a 
state of sustained increased metabolism. As such, it can promote neovascularization. 
The objective of the latter is to answer to the heightened metabolic demand as well as 
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to optimize the delivery of blood components to the affected tissue. Pathologies with 
an inflammatory component and in which the prostanoid prostaglandin (PG) E2 is 
involved are discussed in section 3. 
 
 
1.3 THE IMMUNE SYSTEM 
 
The immune system is an effector mechanism that enables the body to maintain 
homeostasis by dealing with noxious agents and tissue injuries. It has two arms, innate 
and adaptive immunity, which rely on two completely different approaches to defend 
the host. While innate immunity relies on the recognition of evolutionarily conserved 
features of danger (DAMPs), adaptive immunity decomposes assailants and generates a 
response tailored to their constitution.  
 
The recognition of DAMPs by tissue resident immune sentinel cells, like macrophages, 
induces innate immunity. Cytokines and chemokines such as interleukins (IL)-1β, 6 and 
8, tumor necrosis factor (TNF)-α and RANTES are released locally by activated tissue 
cells and immune sentinel cells and in turn recruit and activate neutrophils, monocytes 
and dendritic cells (DCs) from the blood circulation [1]. The latter are phagocytes; 
effector cells of innate immunity that engulf and dispose of microorganisms and 
noxious molecules through a process termed phagocytosis. Innate immunity achieves a 
rapid and efficient response through targeting evolutionarily conserved molecular 
patterns. However, it does not provide a tailored immunity should the noxious agent be 
encountered anew. The latter is a feature of the adaptive immunity. 
 
Phagocytes of the innate immune system serve as a bridge between innate and adaptive 
immunity. DCs for example, digest phagocytosed material and migrate to secondary 
lymphoid organs to present it to T-cells in the context of a major histocompatibility 
complex molecule. When this presentation is supplemented with a co-stimulatory 
stimulus, it causes the activation and expansion of T-cells that recognize the molecule 
presented, also known as an antigen (Ag). In this function, DCs are called antigen-
presenting cells. The activation of T-cells might lead to a humoral response in which B-
cells will produce neutralizing, opsonizing and complement-activating antibodies or a 
cell-mediated immune response. The nature of the response that ensues is dependent 
on the noxious agent against which it is mounted and this is mostly dictated again by 
the regulatory network of mediators through which the cells interact. CD4 T-cells, also 
called T helper (Th) cells, are lymphocytes shaping the adaptive immune response to fit 
the pathogen encountered. There are several functional subsets of Th-cells, Th17 is one 
that will be discussed later. When activated, Th17 cells secrete cytokines that cause an 
amplification of inflammation through the activation tissue cells and the recruitment of 
more phagocytes. 
 
There are billions of T-cells and B-cells each with different receptor specificities. This 
diversity is accomplished through the random rearrangement of lymphocyte receptor 
genes. The random nature of the process makes it theoretically possible and likely to 
generate lymphocytes that recognize self. However, lymphocytogenesis is a tightly 
regulated process and self-recognizing lymphocytes get eliminated through mechanisms 
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termed central and peripheral tolerance. Despite the existence of those mechanisms, 
lymphocytes recognizing self sometimes reach circulation and their activation can lead 
to autoimmunity. 
 
The above description of a classical immune reaction depicts innate and adaptive 
immunity as a continuum, an analysis of the regulatory network of mediators through 
which they interact however, can make one realize that they in fact form a well-
integrated defense system. The adaptive immune system can also feedback to the innate 
immune system by recruiting it, activating in or suppressing it in a manner that gives it 
an added selectivity	   [2]. The Th17 subset mentioned earlier is one example. In the 
pathology of rheumatoid arthritis (RA) described in section 3.1, Th17 cells recognizing 
an autoantigen in the joint are thought to exacerbate inflammation leading to joint 
destruction through the activation of local tissue fibroblasts [3]. The latter exemplifies 
the possible contribution of adaptive immunity to chronic inflammation in the case of 
autoimmunity. 
 
 
2 MEDIATORS OF INFLAMMATION AND IMMUNITY 
 
 
2.1 DAMPs 
 
DAMPs can be seen as a set of evolutionarily conserved molecular patterns recognized 
by cells of the immune system as markers of injury or infection. They are recognized by 
cell surface receptors termed pattern recognition receptors (PRRs) and act as inducers 
of inflammation and the immune response. They are divided in two categories: 
pathogen-associated molecular patterns (PAMPs), which are of exogenous nature and 
signal the presence of bacteria and viruses and alarmins, which are endogenous 
molecules normally confined to the intracellular space where they have specific 
functions, but which can be released to the extracellular space in case of trauma or 
infection. Common examples of DAMPs are: lipopolysaccharides (LPS), foreign nucleic 
acids, heat shock proteins and high mobility group box protein-1 (HMGB1) [4]. The 
latter is more extensively presented below. 
 
 
2.1.1 HMGB1 
 
HMGB1 is a prototypical alarmin. In a healthy cellular environment, it can be found in 
cell nuclei, where it regulates gene transcription, chromatin regulation and DNA repair 
or in their cytoplasm, where it serves as a sensor of exogenous nucleic acid and 
mediates the anti-viral immune response	  [5, 6]. However, HMGB1 can also be found in 
the extracellular environment. It can either be passively released from dying cells or be 
actively secreted by innate immune cells including monocytes, macrophages and DCs in 
response to pro-inflammatory stimuli such as cytokines and PAMPs	  [7-9]. 
 
The characterized receptors via which HMGB1 mediates its alarmin functions include 
TLR2, 4 and 9 as well as the receptor for advanced glycation end products (RAGE). 
HMGB1 binding to these receptors results in the induction of inflammation and innate 
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immunity as described in the previous section, essentially through the activation of the 
NF-κB pathway	  [4]. As such, HMGB1 released to the extracellular environment can be 
inactive, trigger the release of pro-inflammatory mediators or act as a chemotactic 
agent. Alternatively, HMGB1 can mediate inflammation through one additional 
mechanism: it can form complexes with endogenous and exogenous molecules to 
enhance signaling through their respective receptors. Reported molecules with which 
HMGB1 forms complexes include IL-1α and β and LPS	  [10, 11]. This latter function is 
thought to serve in accelerating the initial response of innate immunity to danger. 
HMGB1 has been implicated in many pathological conditions with an inflammatory or 
immune component including RA and systemic lupus erythematosus [12-14].  
 
In collagen-induced arthritis (CIA) and in a spontaneous arthritis model, HMGB1 
blocking therapies have been shown to alleviate both inflammation and tissue 
destruction, indicating the potential importance of HMGB1 in arthritis pathogenesis 
[10, 15, 16]. 
 
Furthermore, in RA, HMGB1 is found elevated in the synovial fluid of patients and, in 
vitro, RA synovial fibroblasts (RASFs) can be induced to produce pro-inflammatory 
cytokines by complexes of HMGB1 and IL-1β or LPS [10, 13]. Paper II describes the 
characterization of cytokines and lipid mediators released by RASFs stimulated with IL-
1β/HMGB1 complexes.  
 
 
2.2 PROSTANOIDS 
 
Phospholipids are commonly recognized as structural monomers forming the cell 
membrane. However, they also serve as a source of fatty acids, which, once 
metabolized by cells, become signaling molecules involved in an array of physiological 
processes. Eicosanoids are one family of signaling lipids predominantly involved in 
inflammation and immunity. They are issued from the metabolism of arachidonic acid. 
A major eicosanoid sub-family, the prostanoid family will be described in this section. 
 
 
2.2.1 OVERVIEW OF THE PROSTANOID PATHWAY  
 
The prostanoid sub-family includes PGE2, PGD2 and PGF2α, prostacyclin (PGI2) and 
thromboxane (TX) A2. By definition, they are formed from the metabolism of 
arachidonic acid (AA) by the cyclooxygenase (COX) enzymes. There are two COX 
isoforms found in mammals termed COX-1 [17-19] and COX-2	  [20, 21]. Both enzymes 
are membrane-bound and localized at the endoplasmic reticulum and nuclear 
membranes [22, 23]. Their expression patterns and functions however, differ. COX-1 is 
a protein ubiquitously expressed throughout all tissues of the body and, as its promoter 
suggests, mostly serves housekeeping functions. COX-2 on the other hand, is an 
inducible protein regulated by a promoter containing typical features of the immediate 
early gene and responding to classical inflammatory stimuli like IL-1β, TNF-α and IL-6 
[24]. Both enzymes metabolize AA into PGH2, which then serves as a substrate for 
terminal prostanoid synthases to produce the five primary prostanoids enumerated 
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earlier (figure 1). Prostanoids exert their biological activities in an autocrine or paracrine 
manner by binding to their cognate cell surface receptors. There are five receptors types 
(EP, IP, DP, FP and TP) corresponding to the five primary prostanoids. Here are the 
documented receptors for each prostanoid: 
 
PGE2 receptors: EP1, EP2, EP3 and EP4 
PGI2 receptor: IP 
PGD2 receptors: DP1 and DP2 
PGF2α receptor: FP 
TXA2 receptor: TP 
 
 
All but one receptor, DP2, are part of the G-protein coupled receptor (GPCR) family. 
Signaling via these GPCRs is achieved through the modulation of intracellular calcium 
or cyclic adenosine monophosphate (cAMP) levels. All prostanoids are very similar in 
structure. As a result, prostanoid receptors are not exclusively binding to the prostanoid 
they are assigned by nomenclature. They can also bind other prostanoids with lower 
affinities [25]. One functional example of this takes place in the cardiovascular system 
where a high concentration of PGE2 can trigger the IP receptor to inhibit platelet 
aggregation [26]. In some cases, prostanoids can also bind to nuclear receptors such as 
peroxisome proliferator activated receptor (PPAR) γ with anti-inflammatory effects 
[27].  
 
 
2.2.2 PGE2 
 
PGE2 can be synthesized by three PGE synthases: microsomal prostaglandin E 
synthase (mPGES) -1 and 2 and cytosolic prostaglandin E synthase (cPGES). It is 
involved in a wide array of physiological processes including regulation of vascular 
pressure, maintenance of the gastro-intestinal integrity, renal functions and female 
reproduction	  [24]. Moreover, PGE2 is a modulator of inflammation and immunity. The 
latter is predominantly accomplished through the induced expression of mPGES-1. 
Like COX-2, mPGES-1 expression is inducible under pro-inflammatory conditions [28, 
29] and these two enzymes are predominantly functionally coupled to generate the 
outburst of PGE2 seen under inflammatory condition [30]. Fibroblasts and vascular 
endothelial cells of an inflamed tissue, as well as activated innate immune cells like 
neutrophils, macrophages and DCs, are all sources of PGE2. They produce it via the 
up-regulation of mPGES-1 expression [25, 31]. The biological activities of PGE2 in 
inflammation basically contribute to all the cardinal signs of inflammation. PGE2 
stimulates vascular smooth muscle cells to cause vasodilatation, which is responsible for 
the redness and heat caused by the increased blood flow in an inflamed tissue [32, 33]. 
It also mediates pain hypersensitization both peripherally and centrally by lowering the 
threshold of activation of nerve endings to pain mediators [34]. 
 
As most major cell subsets of the immune system express at least one of the four EP 
receptors, PGE2 is also an important immunomodulator of both innate and adaptive 
immunity [35].  
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Figure 1: Schematic representation of the prostanoid pathway with emphasis on PGE2 synthesis enzymes. Below the 
cascade are lists of receptors and functions for each of the 5 primary prostanoids as presented in section 2.2. Red-
dotted lines represent inhibitors of dual inhibitors of cyclooxygenases (NSAIDs) and selective inhibitors of COX-2 
(COXibs). Green dotted lines represent pro-inflammatory mediators inducing the expression of COX-2 and 
mPGES-1.
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In innate immune cells, PGE2 reduces the oxidative burst of activated neutrophils and 
inhibits TNF-α production while enhancing IL-10 production in activated 
macrophages and DCs [36-39]. Contrastingly, in macrophages, PGE2 is part of an 
autoregulatory loop up-regulating the expression COX-2 and its own production at the 
site of inflammation [40, 41]. PGE2 modulates the adaptive immune system with effects 
on both B-cells and T-cells. In B-cells, it inhibits the lineage development of B-cell 
precursors and the proliferation of mature B-cells while promoting IgE and IgG1 class 
switch [42-44]. The results from studies on the impact of PGE2 on T-cell proliferation 
are contradictory and point to both inhibitory and stimulatory roles. However, this 
discrepancy could be explained by the fact that the T-cell receptor and EP2/4 are 
competing for the recruitment of the same intracellular signalling molecules. Thus, the 
outcome of stimulation relies on the relative strength of the two stimuli [45]. PGE2 was 
also shown to promote IL-23 expression in DCs and to synergize with the latter 
cytokine to facilitate Th17 expansion [46-48]. 
Another important role of PGE2 is the stimulation of angiogenesis. PGE2 can trigger an 
up-regulation of vascular endothelial growth factor (VEGF) production in vascular 
endothelial cells. The latter acts in an autocrine fashion to stimulate angiogenesis [49]. 
Neovascularization is an important factor in chronic inflammatory diseases and cancer 
as will be discussed later. 
 
Lastly, PGE2 also has a central role in inducing the fever response in the brain, which 
complements inflammation and immunity in creating a hostile environment for 
pathogens.	  [50] 
 
PGE2 is a relatively stable molecule in vitro. In contrast, it has a very rapid turnover rate 
in vivo and is quickly eliminated from tissues and circulation. This elimination is carried 
out by 15-prostaglandin dehydrogenase (15-PGDH), a catabolic enzyme which oxidizes 
PGE2 to an inactive metabolite. 15-PGDH and COX-2 are documented to be capable 
of regulating each other’s expression	  [51]. 
 
 
2.2.3 PGD2 
 
Two enzymes can produce PGD2: lipocalin-type and hematopoietic PGD synthases. In 
the brain, PGD2 is involved in regulating sleep, temperature and nociception	  [25, 52]. In 
the periphery, PGD2 is produced most abundantly by mast cells, but also by 
macrophages, DCs and T-cells. Through its action on DP1, it mediates vasodilatation 
and bronchodilation as wells as inhibition of platelet aggregation. Via DP2 it mediates 
chemotaxis of Th2 cells, basophils and eosinophils. The combination of activities just 
enumerated explains the primary involvement of PGD2 in allergic reactions [25]. 
 
There is a particular interest in the PGD2 pathway for its potential anti-inflammatory 
role. More precisely, 15-deoxy-Δ 12,14 PGJ2 a metabolite of PGD2 produced non-
enzymatically has been characterized to inhibit IL-1β-induced PGE2 production in 
neonatal ventricular myocytes through a PPARγ-dependent mechanism. In the latter 
experimental setup, 15-deoxy-Δ 12,14 PGJ2 caused a down-regulation of COX-2 and 
mPGES-1 expression	  [53]. 
	  	   18	  
2.2.4 PGF2α 
 
PGF2α is mainly involved in the female reproductive cycle and in the regulation of 
myogenesis. It is essential for normal parturition. There is only one receptor for PGF2α, 
the FP receptor and it is not expressed in immune cells or immune system-related 
organs such as the spleen or the thymus. There is thus very little evidence of PGF2α 
involvement in inflammatory or immunological processes. 
 
 
2.2.5 TXA2 
 
TXA2, as its name suggests, is involved in cardiovascular homeostasis. It is produced by 
platelets and modulates their functions by inducing aggregation. It also triggers 
vasoconstriction when binding to its receptor on vascular smooth muscle cells [25]. It 
plays a role in immune responses as well. DCs express the TP receptor. When triggered, 
it inhibits DC-T-cell interactions [54]. TXA2 is an extremely unstable molecule that is 
rapidly hydrolyzed to its inactive metabolite TXB2 in vivo. Measurement of TXB2 levels 
is the method of choice to evaluate thromboxane synthesis in biological fluids.  
 
 
2.2.6 PGI2 
 
PGI2 is primarily known for its role in vascular homeostasis. It is produced by 
endothelial cells and has potent vasodilatory and antithrombotic effects. Basically, PGI2 
opposes the effects of TXB2 released by platelets to maintain cardiovascular 
homeostasis [55]. 
 
In inflammation and the immune system, PGI2 has overlapping functions with PGE2. It 
causes vasodilatation, just like PGE2, when binding to the IP receptor on vascular 
smooth muscle cells and induces pain hypersensitization when acting on peripheral 
nerve endings [25, 55]. In the adaptive immune system, PGI2 acts at several levels 
resulting in both inhibitory and stimulatory effects. It inhibits dendritic cell activation, 
maturation and T-cell stimulatory functions, having an ultimate immunosuppressive 
role on Th2 immunity, but promoting Th1 cell differentiation [56, 57]. At the level of 
differentiated T helper cells, it inhibits the production of both Th1 and Th2 cytokines 
[58]. Just like TXA2, PGI2 has a very short half-life in vivo and its production is 
quantified by the measurement of its metabolite 6-keto PGF1α. 
 
 
2.2.7 TRANSCELLULAR BIOSYNTHESIS 
 
Biosynthesis of a prostaglandin traditionally occurs in a single cell that contains the 
complete set of enzymes required for its production. However, it can also happen via a 
process termed transcellular biosynthesis whereby a prostanoid precursor is transferred 
from one cell to another during cell-cell interactions. Transcellular biosynthesis of 
prostacyclin was demonstrated to occur in vitro when endothelial cells are co-cultured 
with platelets or lymphocytes	  [59]. 
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3 THE INDUCIBLE PGE2 PATHWAY IN PATHOLOGY 
 
As efficient and well-orchestrated as inflammation and the immune system can be, they 
do have imperfections, which can cause or contribute to disease. The immune system 
can break tolerance and turn against self, creating one of the many autoimmune 
diseases. It can also fail to recognize and destroy cells of the body that have become 
anarchic, thus allowing cancer to progress. The inducible PGE2 pathway is involved in 
several pathologies of these natures as will be discussed here. 
 
 
3.1 RA 
 
One autoimmune disease in which the inducible PGE2 pathway is involved and which 
has been the focus of my work is RA. RA is a disease characterized by an autoimmune 
response against the joint tissues. The autoimmune reaction triggers chronic 
inflammation, which eventually leads to synovial hyperplasia and structural damage to 
the cartilage and bone [60]. The etiology of RA remains unknown. However, genome-
wide association scans and epidemiological studies have uncovered several genetic and 
environmental factors such as HLA subtype, autoantibodies and smoking, which 
predispose to RA [61-64]. Moreover, the study of individuals with such predispositions 
has provided some insight into the physiological events leading to disease development. 
For example, the study individuals with serum autoantibodies against citrullinated 
peptides and the rheumatoid factor (considered at a high risk of developing RA), has 
revealed that arthralgia can occur before onset of RA [65]. 
 
In healthy articulations, cartilage and a layer of nourishing tissue called the synovium 
separate adjoining bones. The healthy synovium structure is divided into the lining 
(intimal) layer, which is mainly composed of type A (macrophage-like) and type B 
(fibroblast-like) synoviocytes and sub-lining (sub intimal) layer, which also contains 
scattered blood vessels.  In RA patients, a painful inflammation develops in the 
synovium. It is characterized by the activation of synoviocytes and the recruitment of 
cells of the immune system. Resident cells and immune system cells recruited to the 
joint enter a loop of mutual activation, setting up a chronic inflammation in which the 
hypertrophic synovium tissue invades the cartilage and bone, eventually leading to 
cartilage destruction and bone erosion.  
 
PGE2 is found in large amounts in the synovial fluid of RA patients [66] and inducible 
enzymes of the PGE2 pathway are expressed in the inflamed RA joint [67]. 
Accordingly, this pathway has been reported to contribute to multiple features of the 
disease. The localization of mPGES-1 and COX-2 is characterized in synovial tissue of 
RA patients and their expression is up-regulated in fibroblasts and macrophages of the 
lining and sub-lining layers, as well as in vascular endothelial cells [67]. Interestingly, the 
induction of mPGES-1 and COX-2 expression in the synovium of RA patients was 
described to remain unaffected by TNF blockade and B-cell depletion therapy, pointing 
to the potential of targeting PGE2 synthesis in combination with these two therapies 
[68]. As discussed previously, PGE2 activity contributes to inflammation by triggering 
vasodilatation and pain sensitization in vascular smooth muscle cells and terminal nerve 
endings respectively. This is the case in the RA synovium. One feature of the synovium 
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in chronic joint inflammation is hyperplasia. The rapidly growing tissue undergoes 
neovascularization to respond to the increased metabolic demand. PGE2 contributes to 
angiogenesis by stimulating synovial fibroblasts to produce vascular endothelial growth 
factor [69]. IL-17 and IL-17-producing cells (Th17) are closely related to the pathology 
of RA, as peripheral blood and synovial Th17 cell populations are increased in RA 
patients and correlate with disease activity [70, 71]. As mentioned earlier, PGE2 
synergizes with IL-23 to stimulate Th17 cell proliferation. So, the abundance of PGE2 
in the inflamed RA joint could logically contribute to the development of the Th17 
immune response, which would in turn stimulate the release of pro-inflammatory 
cytokines and promotes bone resorption. The contribution of the inducible PGE2 
pathway is very well characterized in animal models of the disease. In mouse CIA, 
knocking out the mPGES-1 enzyme impairs the adaptive immune response and greatly 
reduces the incidence and severity of the disease [72, 73]. PGE2 administration on the 
other hand, exacerbates the disease with a concomitant increase in IL-17 production in 
the affected joints	   [74]. Furthermore, modulation of PGE2 signaling through the EP4 
receptor has revealed a critical involvement of the latter in CIA, especially in the 
development of the Th17 immune response	   [75]. PGE2 also has a direct influence of 
bone resorption in RA. Under homeostasis, bone remodeling is a dynamic process 
involving cells types with opposing functions: osteoclasts, which remove old bone, and 
osteoblasts, which synthesize new bone. Their functions are regulated by the RANKL-
OPG system. In RA, RANKL, which is released by IL-17-stimulated synovial 
fibroblasts and osteoblasts, initiates osteoclastogenesis and thus tips the balance 
towards bone resorption [76]. In conclusion, PGE2 has already been shown to 
contribute to pain and inflammation in RA and it could potentially have an involvement 
in angiogenesis, Th17 expansion and bone resorption in this disease. These multiple 
involvements of PGE2 in RA make the inducible PGE2 pathway an attractive 
therapeutic target. 
 
 
3.2 MULTIPLE SCLEROSIS 
 
Multiple sclerosis (MS) is another disease where inflammation plays an important role. 
It is commonly considered to be a T-cell mediated disease consisting in an autoimmune 
response attacking the central nervous system and causing demyelination of neuronal 
axons. Very little is known about the inducible PGE2 pathway in MS other than the fact 
that mPGES-1 is expressed in the macrophages of brain lesions [77]. Interestingly, the 
disease is believed to have a Th17 immune component as MS patients experience 
elevated blood and cerebrospinal fluid IL-17 levels, as well as IL-23 expression in DCs 
and active lesions [78]. Experimental autoimmune encephalomyelitis (EAE) is the 
animal model of reference for MS. It results from an autoimmune response against 
myelin antigens and is a T-cell mediated disease, comprising a Th17 component. 
mPGES-1 is characterized to play a key role in EAE: its expression is up-regulated in 
macrophages/microglia of brain lesions and mPGES-1 knockout mice experience 
reduced symptoms in the chronic phase of the disease. The mechanism behind 
mPGES-1 involvement in EAE was partially elucidated as the presence of active 
mPGES-1 was shown to aggravate the inflammation and demyelination associated with 
the disease [77, 79]. Most importantly, mPGES-1 knockout mice experience a lower 
Th1/Th17 burden [77]. 
	  	   21	  
3.3 INFLAMMATORY BOWEL DISEASE 
 
Inflammatory bowel disease (IBD) is a complex group of chronic inflammatory 
disorders characterized by inflammatory reactions to microbial antigens of the 
commensal flora. There are two major forms of IBD: Crohn’s disease and ulcerative 
colitis. IBD is one of the most prominent risk factor for colorectal cancer (CRC).  As 
for CRC, the inducible PGE2 pathway has considerable implications in IBD. An 
increased amount of PGE2 can be detected in the mucosa of IBD patients and it 
correlates with disease activity [80, 81]. This is likely the result of both an increase in 
PGE2 synthesis and a reduction in its catabolism, as the expression of both mPGES-1 
and COX-2 is up-regulated in colonic epithelial cells of IBD patients while that of 15-
PGDH is down-regulated [82-84]. As previously mentioned, PGE2 also performs 
physiological functions in the GI tract, including gastric mucosa protection. Thus, in 
IBD, PGE2 appears to stimulate both the gastro-protection needed to repair the 
damage caused by inflammation and inflammation itself [85]. In an experimental model 
of chemically-induced colitis, the EP4 receptor appears to play a central role in gastro-
protection as EP4 knockout mice experienced a more severe disease. Knocking out the 
other three EP receptors did not have any significant impact in this model [86]. 
 
 
3.4 CARDIOVASCULAR DISEASES 
 
The cardiovascular system is another system where prostaglandins are implicated in 
both homeostasis and pathological conditions. Concerning physiological functions, as 
previously mentioned, PGE2 is involved in the regulation of blood pressure whereas the 
thromboxane/prostacyclin balance plays a central role in platelet activation. 
Cardiovascular diseases constitute a broad range of conditions, which, for most, are 
associated with atherosclerosis. Atherosclerosis is a chronic inflammatory condition. It 
is characterized by a deposition of lipids into the arterial wall, termed atheroma, which 
causes progressive wall thickening. Atheromas are found in most people by age 40 and 
do not pose problem unless they interfere with blood flow by their size or if they 
rupture and cause thrombosis [87]. mPGES-1 expression together with that of COX-2 
is up-regulated in atherosclerotic plaques and PGE2 production was postulated to 
contribute to plaque rupture [88]. In mice, PGE2 is involved in both atherogenesis and 
thrombosis [89, 90]. Moreover, mPGES-1 gene deletion appears to retard atherogenesis 
in the hyperlipidaemic mouse model of atherosclerosis and cause a shift in the 
thromboxane/prostacyclin balance towards the atheroprotective prostacyclin	   [89]. For 
the latter finding, urine metabolites of prostacyclin and thromboxane were measured. It 
is thus a reflection of the systemic levels of the two prostanoids. 
 
 
3.5 CANCER 
 
Interestingly, COX-2 and mPGES-1 are found elevated, whereas 15-PGDH is down-
regulated in a number of cancers [91]. Moreover, the extent of mPGES-1 induction has 
been correlated to poor prognosis in colorectal neoplasms	   [92]. One proposed 
mechanism to explain the involvement of the PGE2 pathway in this pathology is it 
drives lymphangiogenic growth through the up-regulation of VEGF production in 
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stromal cells [92, 93]. Nevertheless, the inducible PGE2 pathway can potentially be 
involved in several other processes regulating oncogenesis and cancer progression. 
Briefly, PGE2 promotes proliferation and survival in neoplastic epithelial cells. It also 
modulates tumor immunosuppression and the inflammatory microenvironment 
creating optimal conditions for tumor progression [91]. PGE2 contributes to the tumor 
inflammatory microenvironment via its previously mentioned involvement in 
vasodilatation and the Th17 response [91]. PGE2 also favors tumor 
immunosuppression by inhibiting cytotoxic T lymphocyte activity and antigen 
presentation in tumor cells and DCs	   [94, 95]. The inducible PGE2 pathway is thus 
contemplated as a therapeutic target in cancer. NSAIDs have already proven to reduce 
the risk of several types of cancers including those of the breast, colon, lung and 
prostate [96]. Moreover, studies using mPGES-1 siRNA knock-down in xenograft 
models of tumorigenesis or mPGES-1 knockout mice in models of intestinal cancer 
both result in impaired growth and survival of tumor cells	  [97]. 
 
 
4 RA THERAPEUTIC APPROACHES AND TARGETING THE PGE2 
 PATHWAY 
 
There are several therapeutic alternatives used in the treatment of RA. The most 
efficient approach is undoubtedly the use of disease-modifying anti-rheumatic drugs 
(DMARDs) as it is the only one able to affect disease progression by slowing down 
joint destruction. However, kinase inhibitors such as the JAK kinase inhibitor 
Tofacitinib have recently become available for RA and could potentially provide more 
disease-modifying treatment alternatives	   [98, 99]. DMARDs can be divided into 
synthetic molecules, classically represented by methotrexate, and biological molecules of 
which TNF blockers are the most prominent players. Methotrexate is characterized to 
treat RA via two mechanisms. First of all, it inhibits dihydrofolate reductase, which 
impairs DNA synthesis and thus inhibits cellular proliferation. Secondly, it triggers a 
rise in adenosine, which has anti-inflammatory properties. The second mechanism is 
the result of substrate build-up after DHF reductase inhibition [100].	  TNF blockers, as 
the name suggests, are either antibodies (Infliximab, Adalimumab) or chimeric 
constructs (Ethanercept), which inhibit TNF signaling by binding to the soluble and 
membrane-bound forms of TNF. In a responsive patient, they reduce inflammation 
and disease activity and increase joint function [101]. Their most important 
contribution is certainly the prevention of cartilage and bone destruction	  [102-104]. B-
cell depletion therapy is another biological approach effective in the treatment of RA. 
Rituximab is a monoclonal antibody against CD20, a B-cell surface marker that 
mediates B-cell depletion by antibody-dependent cellular cytotoxicity [105]. In 
responsive patients, Rituximab is suggested to reduce synovial inflammation through 
the depletion of auto—reactive B-cells	  [106]. Biological DMARDs typically have limited 
side effects and they can be used in combination. As a matter of fact, TNF blockers are 
most efficient at treating RA when combined with methotrexate	  [104]. Glucocorticoids 
administered systemically or intra-articularly are another approach for the treatment of 
RA. They suppress disease activity and reduce inflammation and pain. However, they 
have considerable side effects including osteoporosis and diabetes, which prevent their 
long-term use. Another class of therapeutic agents, which are commonly used to treat 
RA, is COX inhibitors. They were shown to reduce pain and inflammation, but also 
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have side effects precluding their long-term use. COX inhibitors and other approaches 
targeting the PGE2 pathway are presented in detail in sections 4.1 to 4.4. 
 
 
4.1 COX INHIBITION 
 
Cyclooxygenases were the first enzymes of the PGE2 pathway to be targeted for 
therapeutic purpose. In the late 1800s, acetyl salicylic acid, also commercially known as 
Aspirin, was already being manufactured and marketed as a treatment for fever, pain 
and inflammation. It is only later in the 1970s that its target was characterized as COX 
[107]. Aspirin is part of class of drugs called non-steroidal anti-inflammatory drugs 
(NSAIDs), which all target cyclooxygenase enzymes. They are effective anti-
inflammatory drugs. However they have side effects caused by an interference with 
homeostatic functions of prostanoids. Aspirin is a traditional (t)NSAID, i.e. non-
selective COX inhibitor, that has a higher potency for COX-1. During prolonged 
treatment, it interferes with the protective functions of COX-1-derived PGE2 in the 
stomach and is associated with the development of gastric ulcers [108]. As COX-2 is 
the predominant COX isoform involved in inflammation, selective COX-2 inhibitors 
(COXibs) were developed in an attempt to inhibit the synthesis of prostanoids in 
inflammation while sparing their physiological functions. However, these so-called 
COXibs were found to interfere with platelet functions, for which the PGI2/TXB2 
ration is critical. They inhibit COX-2-mediated prostacyclin formation while, sparing 
COX-1-mediated thromboxane synthesis. Therefore, prolonged treatment with 
COXibs leads to platelet activation and an increased risk of thrombosis and myocardial 
infarct	  [109, 110]. 
 
NSAIDs and COXibs are effective treatments for several of the pathologies where 
PGE2 is involved. For example, they can relieve pain and inflammation associated to 
RA, as well as reduce the risk of developing certain cancers [96]. However, most of 
these conditions require long-term use, which is complicated due to their associated 
side effects. 
 
 
4.2 MPGES-1 INHIBITION 
 
mPGES-1 inhibition has been proposed as an alternative to COX inhibition to 
dissociate the anti-inflammatory, anti-pyretic and pain killing effects of NSAIDs and 
COXibs from their gastro-intestinal and cardiovascular side effects. As with COX-2, 
the inducible nature of mPGES-1 creates a certain therapeutic selectivity for pro-
inflammatory environments. Under normal physiological conditions, mPGES-1 
expression is low and found in testis, prostate, placenta, mammary glands and the 
bladder [111]. The protein can also be found constitutively expressed in the lung, 
spleen, kidney and stomach	   [112]. As pointed out in the previous section, the 
therapeutic potential of targeting mPGES-1 is large. As such, several teams are working 
on the development inhibitors and, as a lesson learned from the failures of NSAIDs 
and COXibs, a considerable amount of research now addresses the potential 
physiological consequences of selective mPGES-1 inhibition, to ensure it constitutes a 
viable therapeutic alternative. Prostanoid profiling and targeted lipidomics are two 
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techniques used to study the impact of mPGES-1 inhibition on the prostanoid 
pathway. Prostanoid profiling consists in monitoring the levels of prostanoids and their 
metabolites upon altering mPGES-1 activity, to determine how the pathway reacts to 
the change. Targeted lipidomics is like prostanoid profiling, but additionally evaluates 
the expression of enzymes and receptor of the pathway. The effect of mPGES-1 
inhibition on the cardiovascular system was investigated by Fitzgerald et.al. using a 
mPGES-1 knockout mouse in a model of thrombotic carotid artery occlusion. As 
opposed to selective COX-2 inhibition or IP receptor gene deletion, mPGES-1 gene 
deletion did not accelerate thrombogenesis [113]. This is an indication that mPGES-1 
inhibition is unlikely to cause the cardiovascular side effect seen with COXibs.	   
 
Almost 20 years after the discovery of mPGES-1 and the realization it constitutes a 
therapeutic target, a great deal of literature that has been generated about molecules 
capable of inhibiting its activity or its expression. Naturally, publications characterizing 
endogenous lipids, such as LTC4 or 15-deoxy-∆(12-14)-prostaglandin J2, inhibitors of 
other prostaglandin/leukotriene pathway enzymes, like sulindac or MK-886 and PGH2 
analogs came first as they were readily available for assessment. However, those were 
not optimal for therapeutic mPGES-1 inhibition as they either had intrinsic bioactivities 
or lacked enzyme specificity [29, 114, 115]. Later came molecules issued from rational 
drug design i.e. high-throughput screening (HTS) hits or inhibitors of other enzymes of 
the same family or pathway, which were optimized through structure-activity 
relationship (SAR) studies. Several laboratories attempt to develop potent and selective 
mPGES-1 inhibitors. Table 1 details the best-characterized mPGES-1 inhibitors in the 
literature. 
 
There are two major hurdles in the development of mPGES-1 inhibitors: the 
hydrophobic nature of the target and a species selectivity, which causes most inhibitors 
of the human enzyme to undergo a profound loss of potency with murine mPGES-1. 
Both will be discussed later on. 
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Table 1: mPGES-1 inhibitor characterized in vitro in cellular assay and/or in vivo 
 
 
 
4.2.1 MF63 
 
MF-63 is an mPGES-1 inhibitor produced by scientists at Merck-Frosst. It is the 
product of a HTS campaign, which identified a JAK kinase inhibitor as a hit. The hit 
was then subjected to SAR studies and a lead optimization phase, to yield MF63 (Table 
1). MF63 has an IC50 of 0.001 µM on human recombinant mPGES-1 and a >1000-fold 
selectivity over the other enzymes of the prostanoid cascade [116, 117]. It can inhibit 
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PGE2 synthesis in IL-1β-induced A549 cells but undergoes a considerable loss of 
potency when the assay is performed in high serum concentration [117]. Like most 
mPGES-1 inhibitors published, MF63 is virtually inactive against rat mPGES-1 [116]. 
To be able to study mPGES-1 inhibition in vivo in relevant disease models, Merck-
Frosst has generated a human mPGES-1 knock-in mouse. They also studied MF63 in 
guinea pig models, since it is active against guinea pig mPGES-1. MF63 was found to 
inhibit PGE2 synthesis both centrally (brain) and peripherally, to relieve acute 
inflammation, fever and pain [117]. Moreover, it did not cause gastro-intestinal toxicity 
[117]. In conclusion, the characterization of MF63 validates mPGES-1 as a therapeutic 
target and differentiates it from NSAIDs regarding gastro-intestinal side effects. 
Additional HTS campaigns and SAR studies were conducted at Merck-Frosst, which 
yielded compounds equally potent and in some cases with optimized pharmacokinetic 
profiles	  [118, 119]. Their in vivo efficacy, however, remains to be characterized. 
 
 
4.2.2 PF-9184 and PF-4693627 
 
An mPGES-1 inhibitor was also generated at Pfizer [120]. PF-9184 has an IC50 of 0.016 
µM [121]. Its selectivity however, was only tested against recombinant COX enzymes. 
It was mainly used to characterize the impact of mPGES-1 inhibition on the prostanoid 
profile in cultures of synovial fibroblasts from RA patients, in which it causes a shunt of 
PGH2 to the prostacylin pathway in a short incubation assay, but a reduction in both 
PGE2 and 6-keto PGF1α in a long incubation assay [121].  An inhibition of prostacyclin 
synthase can thus be ruled out, but it remains unclear whether PF-9184 has an 
inhibitory potential on the other prostanoid synthases. PF-9184 has poor aqueous 
solubility and attempts to improve this property unequivocally led to loss of potency. 
Like MF63, PF-9184 is inactive on rat mPGES-1. Pfizer has a second mPGES-1 
inhibitor selected as a clinical candidate: PF-4693627. It is also species selective and 
only inhibits human mPGES-1  (IC50 of 0.003 µM). PF-4693627 inhibits PGE2 
synthesis in a human whole blood assay without interfering with PGD2, thromboxane 
or leukotriene synthesis.  It was shown to inhibit PGE2 synthesis in vivo in the guinea pig 
air pouch model of acute inflammation	  [122]. 
 
 
4.2.3 AF3442 and AF3485 
 
A collaborative effort between industry and academia yield two other mPGES-1 
inhibitors: AF3442 and AF3485. AF3442 has an IC50 of 0.06 µM on recombinant 
human mPGES-1 and it remains to be determined if it can inhibit mouse mPGES-1 
[123]. It was mainly characterized in human monocyte cultures and whole blood assays 
to investigate the impact of mPGES-1 inhibition on COX-1 and COX-2-derived 
prostanoid synthesis. In a 24h LPS-stimulated human monocyte assay, it inhibited 
PGE2 synthesis in a concentration-dependent manner without interfering with the 
production of prostacyclin, TXB2 or PGF2α up to 10 µM. At 100 µM however, AF3442 
partially inhibited TXB2 synthesis [123]. This could be due to thromboxane synthase 
inhibition, as the cross-reactivity of the compound against other terminal synthases of 
the prostanoid cascade was not characterized. AF3442 can also inhibit PGE2 in LPS-
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stimulated whole blood, albeit at a higher concentration due to plasma protein binding 
(EC50= 29 µM) [123]. In both systems, mPGES-1 inhibition could be achieved without 
repercussions on the production of other prostanoids. This group developed a second 
mPGES-1 inhibitor. AF3485 has an IC50 of 0.438 µM in microsomal fractions prepared 
from IL-1β-stimulated A549 cells. It does not cross-react with 5-lipoxygenase (5-LO) 
or other PGES and was further characterized in the context of cancer. AF3485 
inhibition of mPGES-1 in A431 cells resulted in a reduction of epidermal growth factor 
receptor (EGFR) signaling in vitro (EGFR is the receptor for VEGF). This effect 
translated into a reduction in tumor growth when the same cells were used in a 
xenograft model and AF3485 was administered to mice i.p. It further validates 
mPGES-1 as a target in cancer [124]. 
 
 
4.2.4 DUAL INHIBITORS OF MPGES-1 AND 5-LO 
 
A German group is also working on dual inhibitors of mPGES-1 and 5-lipoxygenase, 
the hub enzyme in the leukotriene synthesis pathway. They recently published a series 
of natural compounds and pirinixic acid derivatives capable of doing so. Two of these 
compounds named YS121 and 7a have respective IC50 of 3.4 µM and 0.6 µM on 
human recombinant mPGES-1[125, 126]. They were also characterized in vivo in a rat 
model of acute inflammation, but it remains unclear whether they have any specific 
activity on rat mPGES-1. Several pirinixic acid derivatives including YS121 are 
characterized to be agonists of PPAR, which inhibit inflammation [127]. 
 
 
4.3 EP RECEPTOR AGONISM / ANTAGONISM  
 
EP receptors have been considered as therapeutic targets for several decades. As such, 
there is an extensive list of agonists and antagonists of EP receptors 1 to 4, which have 
been used as tools to characterize the functions of each receptor as well their potential 
for therapy [128]. One problem with EP receptors as therapeutic targets is that they 
have overlapping functions and their involvement in pathologies is often contrasted by 
homeostatic functions. For example, EP3 receptor stimulation promotes tumor 
angiogenesis, but it also has gastro protective functions making it an unlikely candidate 
target [128]. Nevertheless, EP receptors are still contemplated as therapeutic targets. 
For example, Merck-Frosst has developed an EP4 antagonist, which relieves pain and 
inflammation in models of arthritis without causing gastro-intestinal toxicity	  [129]. 
 
 
4.4 15-PROSTAGLANDIN DEHYDROGENASE EXPRESSION 
 
As previously mentioned, 15-PGDH expression is down-regulated in several cancer 
[91]. As it has a potential tumor suppressor activity via PGE2 elimination, approaches 
are being developed to induce its expression to reverse carcinogenesis. Interestingly, 
thiazolidinediones, an epidermal growth factor receptor tyrosine kinase inhibitor, TGFβ 
and certain NSAIDs have all been shown to stimulate the expression of 15-PGDH in 
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cancer cells [130]	   [131-133]. Modulation of 15-PGDH expression also constitutes an 
interesting therapeutic approach for other pathologies where PGE2 is involved. 
 
 
5  METHODOLOGY 
 
 
5.1 SYNOVIAL BIOPSY MATERIAL AND RASFs 
 
In the first part of this thesis, the prostanoid cascade was studied to further characterize 
its involvement in arthritis as well as to evaluate how it is affected by MTX treatment. 
To achieve these objectives, we used synovial biopsy material and cultured synovial 
fibroblasts isolated from RA patients. As previously mentioned, the inducible PGE2 
pathway is up-regulated in synovial biopsies of RA patients and their cellular 
localization includes synovial fibroblasts, making the following two biological materials 
relevant to our studies [67]. 
 
The study of synovial biopsy specimens is an established and trusted method to 
evaluate disease mechanisms, response to treatment and prognosis, as the immuno-
histological features in synovial tissue consistently reflect disease status [134]. We used 
synovial biopsy specimens in paper I to verify whether the PGE2 pathway was up-
regulated in individual considered at risk of developing arthritis. We also used biopsies 
in paper III to characterize the synovial expression of 15-PGDH in arthritis patients 
and to investigate the impact of MTX treatment on the synovial expression of the 
enzymes of the PGE2 pathway. 
 
Synovial fibroblasts isolated from RA patients are one of the reference cell systems 
used to study the molecular pathways involved in this disease. Synovial fibroblasts 
mediate both cartilage and bone destruction in RA. Moreover, they specifically 
contribute to the chronic inflammatory loop that characterizes RA via the production 
of numerous cytokines and chemokines and prostaglandins [135]. In paper II, we used 
RASF cultures to characterize a potential new trigger for the induction of PGE2 
synthesis in RA. We also used RASFs in paper III to characterize their expression of 
15-PGDH after IL-1β stimulation and to investigate the impact of MTX treatment on 
enzymes of the PGE2 pathway in that cell type. In paper IV, RASFs were also used in 
the characterization compound II, because they up-regulate the expression of mPGES-
1 when stimulated with IL-1β and TNF-α. 
 
 
 
5.2 MPGES-1 INHIBITOR CHARACTERIZATION IN CELLULAR 
ASSAYS 
 
In the second part of the thesis mPGES-1 inhibitors were developed. After the 
characterization of their potency on recombinant mPGES-1 and cross-reactivity on 
other enzymes of the prostanoid cascade, compound II and III were assayed in relevant 
cellular systems. 
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5.2.1 A549 SHORT AND LONG INCUBATION ASSAYS 
 
A549 cells are a lung carcinoma cell line reported to express mPGES-1 and COX-2 at 
high levels after IL-1β stimulation. The expression of mPGES-1 is functionally relevant 
for A549 cells. mPGES-1 knock down has been reported to impair their clonogenicity 
in vitro and their tumorigenic potential in vivo [136]. They were also previously used in 
the development of mPGES-1 inhibitors [116, 126]. In papers IV and V, we used A549 
cells in an assay to address the on-target/off-target effects of our mPGES-1 inhibitors. 
We first investigated whether compounds II and III could inhibit PGE2 synthesis in an 
assay where they are present for the entire time of the cytokine stimulation (long 
incubation assay). Then, to ensure that a reduction in PGE2 synthesis happens 
specifically through the inhibition of mPGES-1, we perform a short incubation assay 
where compounds are only in the presence of mPGES-1 expressing cells for 30 mins. 
The latter allows us to eliminate the hypothesis that PGE2 synthesis inhibition in the 
long incubation assay happens through an off-target side effect interfering with the up-
regulation of the inducible PGE2 pathway enzymes. 
 
 
5.2.2 MOUSE AND RAT PERITONEAL MACROPHAGES 
 
Macrophages are innate immune cells characterized to induce the PGE2 pathway when 
stimulated with LPS.  As previously mentioned, there is a species selectivity issue with 
most mPGES-1 inhibitors and we used peritoneal macrophages isolated from mice and 
rats to investigate the activity of compound II and III in mouse and rat cell cultures. 
 
 
5.2.3 BLOOD AND BLOOD-DERIVED ASSAYS 
 
To investigate how compounds II and III performed in the presence of serum proteins, 
e used the whole blood assay developed by Brideau et. al. in the development of  
NSAIDs [137]. Also, as we did not have access to enzymatically active recombinant 
thromboxane synthase, we instead isolated platelets from whole blood as a source of 
COX-1-derived TXB2 to investigate the cross-reactivity of compounds II and III on 
thromboxane synthesis. Worthy of mention, platelets do not express mPGES-1 [123]. 
 
 
5.3 MPGES-1 INHIBITOR CHARACTERIZATION IN VIVO 
 
 
5.3.1 AIR POUCH MODEL 
 
The air pouch model of acute inflammation was developed by Edwards, et. al., as an in 
vivo model to study the functioning of the synovium	   [138, 139]. Once mature, air 
pouches have a lining that is similar in composition to the synovial membrane. The air 
pouch model was used in the development of COXibs [140]. We used this model with 
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carrageenan as a inflammatory trigger to determine whether compound II and III 
administered intra-peritoneally could inhibit PGE2 synthesis. 
 
 
5.3.2 AIA 
 
The AIA model was the first experimental model of arthritis developed [141, 142]. It 
has a clinical onset and course resembling that of reactive arthritis in humans and 
essentially starts with a synovitis leading to cartilage and bone destruction. 
 
The AIA model can be performed in two different ways with the complete Freund’s 
adjuvant being injected either at tail base or in one limb. The second variant was used in 
paper IV as it allowed us to study an acute (ipsilateral paw) and a delayed (contra-lateral 
paw) inflammatory reaction. These two reactions were relevant for the characterization 
of compound II as mPGES-1 and COX-2 are up-regulated in the injected paw 
throughout the course of inflammation, but they are not up-regulated in the inflamed 
contra-lateral paw in AIA [143]. 
 
 
5.4 QUANTIFICATION OF PROSTANOIDS AND EVALUATION OF 
 THE ENZYMES INVOLVED IN THEIR SYNTHESIS 
 
The methodologies described up to this point were selected for the common feature 
that they allowed the study of the prostanoid pathway and more precisely the PGE2 
pathway and the enzymes involved in its synthesis. To quantify prostanoids, we used 
commercially available antibody-based enzyme immunoassays or a prostanoid profiling 
protocol by mass spectrometry developed in our lab. To characterize the expression of 
enzymes of the PGE2 pathway, we used immunohistochemistry (IHC) and Western 
blotting. 
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6 RESULTS AND DISCUSSION 
 
The first section of the results and discussion serves as a further characterization of the 
PGE2 pathway in RA. The second section investigates mPGES-1 as a therapeutic target 
in inflammation through the characterization of novel selective mPGES-1 inhibitors 
and the use of the mPGES-1 knockout mouse. 
 
6.1 INVOLVEMENT OF THE PGE2 PATHWAY IN RA 
 
Effective RA therapies such as methotrexate, TNF blockers and B-cell depletion have 
revolutionized the care of patients living with RA and tremendously improved their 
quality of life by slowing down disease progression. Nevertheless, these therapies don’t 
bring disease progression to a complete halt, nor do they reverse its course. Therefore, 
there must remain inflammatory and/or immune pathways left unaltered which 
continue to drive disease progression. The inducible PGE2 pathway is a likely candidate, 
as it is up-regulated in the synovium of RA patients	   [144] and the expression of 
mPGES-1 remains unchanged following treatment with TNF blockers or B-cell 
depletion agents [67, 68]. This section of the thesis serves as a further characterization 
of the PGE2 pathway in RA, supporting the hypothesis that mPGES-1 is a relevant 
therapeutic target with potential benefits through combination with anti-rheumatic 
therapeutic agents leaving its induction unaltered. 
 
 
6.1.1 THE PGE2 PATHWAY AND THE PRE-CLINICAL AND EARLY 
 CLINICAL PHASES OF ARTHRITIS. 
 
The etiology of RA remains elusive. However, decades of research have helped to 
define genetic susceptibility traits, biomarkers and prodromal symptoms that, together, 
constitute a set of features useful in identifying individuals with an increased risk of 
developing the disease. In paper I, we assembled and studied a cohort of individuals at 
an increased risk of developing arthritis based on two criteria: 
 
1. Prodromal arthralgia and/or positive family history of RA 
2. Circulating serum autoantibodies recognizing rheumatoid factor 
  and/or citrullinated peptides. 
 
The rationale behind the choice of those two criteria is as follows: autoantibodies have 
been characterized as biomarkers representing an on-going systemic pre-clinical phase 
of disease [145-147] and prodromal arthralgia has been described to occur in individuals 
several years before the first clinical manifestations of arthritis [65]. The molecular 
mechanisms from which prodromal arthralgia originates however, remain to be 
characterized, but PGE2 constitutes a prime candidate. As previously mentioned, PGE2 
functions as a pain mediator both centrally and peripherally. Additionally, the up-
regulation of the inducible PGE2 pathway has previously been reported in the clinical 
phase of RA and other forms of arthritides [66, 144, 148, 149]. 
  
The first part of paper I describes the study of the PGE2 pathway in a cohort of 
individuals with an increased risk of developing arthritis. We investigated the hypothesis 
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that the synovial expression of enzymes of the PGE2 pathway would either be 
correlated to pain sensation or predict disease development. Interestingly, the rationale 
behind the elaboration of the hypothesis came from experimental arthritis model 
studies, in which pain sensitization [150] and synovial mPGES-1 up-regulation [151] 
were characterized to take place before onset of disease.  
 
We evaluated the expression of mPGES-1, COX-1, COX-2 and 15-PGDH in subjects 
synovial biopsies by IHC. The hypothesis could not be confirmed, as no correlation 
could be established between the expression of the aforementioned enzymes and 
quantitative pain assessment or arthritis development. However, a trend towards higher 
expression of COX-1, COX-2 and 15-PGDH was detected in individuals with 
arthralgia (data not shown and paper I, figure 1). 
 
One limitation with the study of the pre-arthritis cohort was the design of the synovial 
biopsy sampling procedure. Due to the intrinsic thinness of the synovial membrane in 
joints bearing no clinical sign of inflammation, a large joint (the knee joint) was 
designated for biopsy sampling; that regardless of its symptomatic status.  
 
Since the PGE2 cascade can mediate pain sensitization both centrally and peripherally, 
two possible mechanisms of action had to be considered when addressing our 
hypothesis: 
 
1. The PGE2 cascade would be part of a systemic pre-clinical phase of disease, in 
which case modulation of enzyme expression could be expected in symptomatic 
and asymptomatic joints alike.  
 
2. The PGE2 cascade would be part of a local pre-clinical phase of disease, in 
which case modulation of enzyme expression would be expected in 
symptomatic joints only. 
 
When addressing our hypothesis with the latter mechanism in mind, the arthralgia 
patient sub-groups had to be further stratified into two groups i.e. those for which 
biopsy sampling occurred in an symptomatic knee and those for which biopsy sampling 
occurred in a asymptomatic knee (figure 2) While the inclusion criteria had already 
limited the number of individuals recruited to this cohort, the division of the arthralgia 
patient sub-group unfortunately left us with a very limited number of individual per 
group to perform our analyses. However, subjects are constantly being recruited to the 
pre-arthritis cohort and this study could very well be extended to include a greater 
number of subjects in the future. 
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In the second part of paper I, we investigated PGE2 pathway enzymes in an early 
arthritis cohort and whether their expression correlated with pain sensitization at this 
stage of disease development. The early arthritis cohort was composed of patients 
recruited less than a year after arthritis diagnosis and which, two years later, received a 
definite diagnostic classification of undifferentiated arthritis, spondyloarthritis (SpA) or 
RA. No correlation could be found in this cohort between pain sensitization and PGE2 
pathway enzyme expression at baseline (paper I, table 3). We did however report a 
correlation between mPGES-1 and COX-1 and the number of macrophages present in 
the synovium. (paper I, supplemental table 1) This could be expected, as PGE2 is a 
mediator of vasodilatation and is therefore contributing to cellular infiltration. 
 
When the cohort was stratified according to definite diagnostic classification after two 
years however, baseline mPGES-1 and COX-1 levels were found higher in the SpA 
group compared to the RA group (p=0.001 and p=0.003 respectively), consistent with 
previous findings and supporting the idea that PGE2 produced via mPGES-1 plays a 
role in SpA through an effect on osteoblastogenesis [148, 152]. 
 
Figure 2: The arthralgia sub-group from the cohort of individuals at risk of 
developing arthritis. Red dotted line: the division necessary to investigate our 
hypothesis if we assume the PGE2 cascade has a local involvement in 
disease. 
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Although the study in paper I does not point to an involvement of the PGE2 pathway 
in pre-clinical or early clinical arthritis peripheral pain sensitization, it does not refute 
the hypothesis that the PGE2 pathway could be involved in pain sensitization centrally, 
or in arthritis initiation through a completely different mechanism. As an example, the 
PGE2 pathway is reported to be involved in Th17 cell differentiation and could be 
affecting arthritis pathogenesis through this process [47, 48]. 
 
 
6.1.2 THE MECHANISMS OF UP-REGULATION OF THE INDUCIBLE 
 PGE2 PATHWAY IN RA 
 
The characterization of mPGES-1 and COX-2 expression in RA revealed the two were 
co-expressed in the synovial lining and sub-lining [67]. When RASFs are studied in vitro, 
they can be stimulated to induce COX-2 and mPGES-1 expression by several different 
pro-inflammatory cytokines [28, 144]. IL-1β is one cytokine involved in RA, able to 
induce mPGES-1 expression [28, 153, 154]. Interestingly, IL-1β was also demonstrated 
to mediate inflammation through an additional mechanism, which involves the 
formation of complexes with the alarmin HMGB1 [10]. The expression levels of 
HMGB1 and mPGES-1 in the RA synovium are similarly affected by RA therapies with 
no impact following anti-TNF-α therapy but a reduction following intra-articular 
glucocorticoid treatment [67, 155, 156]. This evidence suggests a potential link between 
HMGB1 and mPGES-1. 
 
In paper II, we investigated whether IL-1β/HMGB1 complexes could modulate the 
PGE2 cascade in RASFs. We found out that IL-1β/HMGB1 complexes induce PGE2 
synthesis in RASF (paper II, figure 1), and that this induction happens through 
activation of the IL-1 receptor I (paper II, figure 6), causing an up-regulation of 
mPGES-1 and COX-2 expression (paper II, figure 3). 
 
In a characterization of the kinetics of release of PGE2 and cytokines, we also 
demonstrated that PGE2 was produced at an earlier time point compared to the 
cytokines IL-6, IL-8, MCP-1 and RANTES (paper II, figure 2) and that inhibition of 
COX-2-derived prostaglandin synthesis with NS-398 reduced the release of IL-6 and 
IL-8 (paper II, figure 4). This suggests an involvement of COX-2-derived 
prostaglandins in the cytokine response. PGE2 and PGI2 were the two prostanoids up-
regulated by IL-1β/HMGB1 complexes in this system (paper II, figure 5). PGE2 has 
already been reported to contribute to the IL-6 response in IL-1β-stimulated RASFs. 
However, the experimental setup used in the previous investigation could not help 
clarify whether PGI2 was also involved [69]. Regardless, this characterization constitutes 
a new and additional mechanism by which the PGE2 cascade can be up-regulated in 
RA. Given their previously reported similar expression patterns in RA following 
treatment, mPGES-1 and HMGB1 represent therapeutic targets, which could confer 
additional benefits when combined with the current therapies of choice. 
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6.1.3 PGE2 CATABOLISM AND THE IMPACT OF METHOTREXATE 
 (MTX) THERAPY IN RA. 
 
The anabolic part of the PGE2 pathway is very well characterized in RA, especially the 
tissue distribution of mPGES-1 and COX-2 and how their expression remains 
unaffected by TNF blockers and B-cell depletion agents [67, 68]. Much less in known, 
however, about 15-PGDH, the enzyme that degrades PGE2, in the same disease or the 
effect of MTX therapy on the PGE2 pathway.  
 
In paper III, we attempted to characterize the expression and tissue distribution of 15-
PGDH in the healthy and arthritic synovium using IHC. We also investigated the 
impact of MTX treatment, another effective therapeutic agent, on 15-PGDH, COXs 
and mPGES-1 expression in the arthritic joint. 
 
15-PGDH localized to the lining macrophages and sub-lining fibroblasts, as well as in 
the endothelium of blood vessels. This is consistent with the previously characterized 
localization of mPGES-1 and COX enzymes in RA synovial tissue and suggests a 
concerted activity of the anabolic and catabolic parts of the PGE2 cascade into 
regulating PGE2 levels in the joint. The promoter of the 15-PGDH gene contains 
potential AP-1 and CREBP binding sites which suggests its expression can be 
modulated in inflammation and immunity by factors such as cytokines [157]. In fact, 
IL-6 and TGF-β are known to regulate its expression in cancer cell lines [158, 159]. 
 
In synovial tissue, we found the expression of 15-PGDH to be slightly up-regulated in 
arthritis patients (paper III, figure 1). MTX, however, did not affect its expression, or 
that of mPGES-1 or COX-2 in RA patients after 8 weeks treatment, adding to the list 
of therapies that leaves the induced PGE2 pathway unaltered.  
 
In conclusion, most of the current RA therapies don’t affect the expression of mPGES-
1 in the RA synovium. This is most likely due to the redundant nature of pro-
inflammatory cytokine networks known to induce the PGE2 pathway in RA synovial 
cells [28]. In line with this principle, in paper II we have characterized a new 
mechanism by which IL-1β can induce PGE2 synthesis in RASFs. As redundant 
networks of mediators regulate its expression, mPGES-1 constitutes an attractive 
therapeutic target for RA treatment that could either be targeted alone or in 
combination with other therapies that leave the PGE2 pathway unaffected. 
 
 
6.2 MPGES-1 AS A THERAPEUTIC TARGET 
 
As elaborated previously in the introduction, mPGES-1 constitutes a prime target for 
drug development. It is reported to be involved in a wide range of pathologies, several 
of which represent markets of sizes large enough to cover development costs and 
generate profit in the long run. 
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Several groups are currently developing molecules that target mPGES-1. Most 
approaches attempt to interfere with its enzymatic activity while one group developed 
an inhibitor of mPGES-1 expression [116, 120, 123, 124, 160]. 
 
There are two major hurdles to overcome in the development of mPGES-1 inhibitors. 
The first one is the hydrophobic nature of its proposed active site. It is lodged inside 
the phospholipid bilayer between subunits of the mPGES-1 homotrimer. [161] As a 
result, the candidate molecules developed also tend to be hydrophobic and perform 
poorly in assay with high serum concentration or in whole blood [114]. This is most 
likely due to high protein binding. The second hurdle resides in key amino acid 
sequence differences within the active site, between human and murine mPGES-1 
orthologs. The three amino acids are bulkier in the murine version of the enzyme. One 
hypothesis is that this bulkiness prevents most human mPGES-1 inhibitors to access 
the active site of the murine enzyme [162]. Both hurdles compromise the feasibility of 
in vivo studies.  
 
The mPGES-1 inhibitors MF-63, developed by Merck-Frosst, and PF-9184, developed 
by Pfizer, are good examples of how these hurdles can hinder development [116, 120]. 
MF-63 and PF-9184 have respective IC50 of 0.001µM and 0.016µM on recombinant 
human mPGES-1 (Table 1). Nevertheless, they have drastically reduced potency on rat 
mPGES-1. Moreover, in the human whole blood assay, their EC50 rises to 1.3µM and 
50µM respectively [116, 121]. Attempts to increase the solubility of PF-9184 during 
SAR studies consistently resulted in loss of potency [120]. Other groups have 
encountered the same hurdles [123, 125]. Merck however, after additional SAR and lead 
optimization studies, has generated new mPGES-1 inhibitors, which retain a greater 
fraction of their recombinant enzyme efficiency in serum-containing assays [119, 163]. 
 
In Papers IV and V, we describe the in vitro and in vivo characterization of two mPGES-
1 inhibitors, compound II and compound III, which were developed at NovaSAID AB, 
following a screening campaign that generated hit compounds which were subsequently 
optimized through SAR and lead optimization studies. Both compounds have 
inhibitory potential towards human and rat mPGES-1. While compound II inhibits 
recombinant human and rat mPGES-1 with similar IC50 (1.8 and 0.62 µM respectively), 
compound III was clearly more potent on the human enzyme (IC50= 0.09µM) than on 
the rat ortholog (IC50= 0.9µM). The mode of inhibition of compound III remains 
unknown and the biochemical characterization revealed that of compound II to be 
mostly competitive of PGH2 [164]. There is no report regarding why compound II and 
III have inhibitory potential on rat mPGES-1, but most likely, their structure allows 
them to overcome the added bulkiness of the rat enzyme’s active site. 
 
As presented in papers IV and V, compounds II and III are also the only mPGES-1 
inhibitors reported to inhibit PGE2 synthesis in vivo in native murine models. We 
addressed their potential in the treatment of inflammation related to arthritis using the 
air pouch and adjuvant-induced arthritis (AIA) models. The involvement of the 
inducible PGE2 pathway is well characterized for both models [143, 165] and they were 
previously used in the development of NSAIDs [165, 166].	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The air pouch model was originally developed as a model to study synovial 
inflammation [138]. The pouch lining is populated by type A (macrophage-like) and 
type B (fibroblast-like) cells and scattered blood vessels [138]. Forming a closed cavity, 
the mature air pouch is very useful to study a local inflammatory reaction. 
 
AIA, in the form we used, involves both an acute (injected paw) and a delayed (contra-
lateral paw) inflammatory response. mPGES-1 and COX-2 are up-regulated in the 
injected paw throughout the course of inflammation, but they are not up-regulated in 
the inflamed contra-lateral paw [143]. In paper IV, compound II reduced the paw 
swelling in both the ipsilateral and contra-lateral paws. The inhibition of edema in the 
contra-lateral paw suggests an impact of compound II on general mechanisms of 
inflammation away from the paw. As mentioned previously, PGE2 can synergize with 
IL-23 to enhance Th17 expansion. Interestingly, in AIA rats an IL-17 response is 
detectable in serum before disease onset [167]. Thus, the effect seen with compound II 
on contra-lateral paw inflammation could be through inhibition of the IL-17 response. 
 
In reaction to the report that cardiovascular complications associated to long-term 
COXibs treatment were likely caused by a modulation of the blood TXB2/PGI2 ratio	  
[168], scientists working on mPGES-1 as a therapeutic target have been trying to 
determine the impact of mPGES-1 inhibition on the prostanoid profile. 
 
Reports about the faith of PGH2 in systems where the mPGES-1 gene has been deleted 
or after treatment with an mPGES-1 inhibitor, point to an assay-dependent outcome 
where cell type, activation state and genetic background can all have an impact [72, 112, 
117, 121, 123, 169]. This is most likely due to the relative expression of PG synthases, 
which differs from one cell type to the next. Additionally, heterogeneity in the 
expression of prostanoid receptors in different cells should also be considered, as there 
exist regulatory feedback loops in the prostanoid pathway [41]. Interestingly, 
considering the complexity of the arachidonic acid cascade, Kihara et. al. developed a 
targeted lipidomics and transcriptomics approach to monitor eicosanoid levels as well 
as the expression of enzymes and receptors of the arachidonic acid cascade 
simultaneously in a given tissue [77]. 
 
Using several of the in vitro and in vivo inflammation assays reported in paper IV and V, 
we have investigated the impact of mPGES-1 inhibition with compound II and III on 
the prostanoid profile. The results, in line with the previous investigations mentioned 
above, turned out to be dependent on experimental conditions. Compound II triggered 
a general down-regulation of prostanoid synthesis in rat peritoneal macrophages while it 
caused a significant reduction of 6-keto PGF1α and PGD2 levels in the rat air pouch 
model. Compound III on the other hand was associated with a shunting of PGH2 into 
the prostacyclin pathway in the A549 short incubation assay and a trend towards 
general down-regulation of prostanoid synthesis in the mouse air pouch model. 
 
In light of the heterogeneity of results concerning the impact of mPGES-1 inhibition 
on the prostanoid profile, a conclusion could be that a characterization can only be 
useful and conclusive if it is performed in the exact system where the outcome is of 
interest. If the cardiovascular side effects of mPGES-1 inhibition are in focus, a 
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prostanoid profile should be performed in the blood circulation of treated animals. If 
the outcome of mPGES-1 inhibition on the inflamed synovium is investigated, a 
prostanoid profile should be performed in the air pouch model, as presented for 
compound II and III in papers IV and V. With the same rationale, if we want to 
compare the data we generated on the impact of compound II and III on the 
prostanoid profile at the site of inflammation with the data generated with other 
mPGES-1 inhibitors, it should only be done if the exact same system was used. The 
A549 long incubation assay we used for the characterization of compound III was also 
used by Merck-Frosst for MF63. Both compounds inhibited PGE2 synthesis in a 
concentration-dependent manner, causing a shunt of excess PGH2 into the PGF2α 
pathway [117] (figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If the impact of mPGES-1 inhibition on the PG profile in a given system should be 
consistent from one inhibitor to the next, provided they are specific, one should be 
careful when comparing gene deletion and enzyme inhibition results. Gene knockout of 
one enzyme of the arachidonic acid pathway has previously been shown to alter the 
expression pattern of other enzymes. In the brains of COX-2 knockout mice, the basal 
expression of cPLA2, sPLA2 and COX-1 are up-regulated while that of mPGES-2 is 
down-regulated, highlighting a compensatory mechanism developed in that genetically 
modified animal [170]. Moreover, in the case of pharmacological inhibition of mPGES-
1, an impact different from that seen with mPGES-1 gene deletion can be expected. In 
contrast to gene deletion, pharmacological inhibition is to a certain extent partial, and it 
leaves the mPGES-1 enzyme expression unaltered. In paper V and VI we have 
therefore investigated mPGES-1 inhibition as well as genetic deletion in LPS-induced 
peritoneal macrophages, to verify if they had equivalent effects on the PG profile. 
Figure 3: Inhibition of mPGES-1 with compound III in A549 cells 
stimulated with IL-1β for 24h exposed a shunt of PGH2 to the PGF2α 
pathway. This confirms results obtained by Merck with MF63. 
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While mPGES-1 knockout macrophages experienced a clear redirection of PGH2 into 
thromboxane synthesis, compound III caused a shunt into the prostacyclin pathway. 
We have also compared the two in the mouse air pouch model using mPGES-1 wild 
type and knockout mice. While mPGES-1 gene deletion was associated with shunting 
of PGH2 into the thromboxane pathway, mPGES-1 inhibition led to a trend of general 
down-regulation of the other prostanoids present. One explanation for the differences 
could be an alteration in the expression of enzymes of the prostanoid pathway, as 
characterized for COX-2 knockout mice or simply that mPGES-1 pharmacological 
inhibition is partial and not sufficient for shunting to occur. Therefore, in the study of 
mPGES-1 as a therapeutic target, it will be very important to complement results 
obtained from studies using knockout mice with investigations using mPGES-1 
inhibitors in the wild type system.	  
 
Revisiting the issue of the PG profile resulting from mPGES-1 inhibition at the site of 
inflammation, one scenario has been proposed by several scientists: the redirection of 
PGH2 into the PGD2 pathway. One metabolite of PGD2 is 15-deoxy-Δ 
12, 14 PGJ2, an 
anti-inflammatory molecule which exerts its actions in part through modulation of the 
PPARγ pathway [171]. Therefore, according to this scenario, if mPGES-1 inhibition 
would not only attenuate pro-inflammatory pathways, but importantly also redirect 
excess PGH2 into an anti-inflammatory pathway (see figure 1). In paper VI, to 
investigate the potential repercussion of mPGES-1 gene deletion on the arachidonic 
acid cascade, we have performed the eicosanoid profile of wild type versus knockout 
mouse peritoneal macrophages between 4 and 16 hours after LPS-induction. 15-deoxy-
Δ 12, 14 PGJ2 was found elevated in knockout compared to wild-type macrophages at 8 
and 12h post-induction. This result suggests a redirection of PGH2 into the PGD2 
pathway is indeed occurring in this system. 
 
If mPGES-1 inhibition and gene deletion can cause an alteration of the prostanoid 
profile, another plausible scenario to be considered is that it could also affect the levels 
of precursors of PGE2 and COX enzyme substrates such as arachidonic acid and 
eicosapentaenoic acid (EPA) in the phospholipid bilayer, and thus eventually alter the 
lipid composition of systems where it is normally active. Such an outcome has already 
been reported for cPLA2 and COX-2 knockout mice. These altered lipid profiles, 
together with gene compensatory mechanisms, led to differences in the arachidonic 
acid metabolism of knockout animals [172, 173]. 
 
In paper VI, we therefore investigated if mPGES-1 gene deletion also altered the fatty 
acid profiles of the brain and spleen under homeostatic and pro-inflammatory 
conditions. We specifically investigated brain and spleen fatty acid profiles, since the 
brain was the subject of the previous reports and the spleen has a constitutive 
expression of mPGES-1	   [112]. Under homeostatic conditions, the brain fatty acid 
profile of mPGES-1 knockout mice was not different from that of wild type animals. 
Their spleen fatty acid profile, however, exposed a significant reduction in the total 
levels of monounsaturated fatty acids (MUFA) and an increase in the Polyunsaturated 
fatty acids (PUFA) eicosadienoic acid (EDA). The latter has previously been shown to 
alter the responsiveness to inflammatory stimuli	   [174]. Together, the results presented 
in paper VI point to several mechanisms by which mPGES-1 inhibition could 
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contribute to both a reduction of inflammation and an enhanced contribution of anti-
inflammatory pathways. It will be of primary interest to validate these results obtained 
in mPGES-1 knockout mice with corresponding mPGES-1 inhibitor studies. 	  	  
7 FUTURE PERSPECTIVES 
 
This thesis has contributed to the characterization of the PGE2 pathway in the 
pathology of arthritis and to the validation of mPGES-1 as a therapeutic target in 
inflammation. More importantly, it has generated the next series of questions to be 
answered in this field of research and produced tools, in the form of compound II and 
III, which will be instrumental in addressing some of them. 
 
The study presented in paper I could not establish a correlation between the expression 
of enzymes of the PGE2 pathway and pain or disease development in pre-clinical and 
early clinical arthritis. Nevertheless, it would be interesting to investigate whether the 
PGE2 pathway is associated to other disease parameters. For example, VEGF-induced 
angiogenesis and Th17 development are two processes known to occur in RA and for 
which mPGES-1 plays a role [69-71]. It would therefore be useful to determine if 
mPGES-1 expression can be associated with markers of these two processes in RA 
patient material. In the event of a correlation, compound II and III could then be used 
to investigate the impact of mPGES-1 inhibition on the two processes in CIA, a model 
in which VEGF-derived angiogenesis	  [175] and Th17 cells [74, 75] are both reported to 
influence disease progression. 
 
The results presented in paper III highlight an incapacity for MTX treatment, despite its 
efficacious treatment of RA, to impact the up-regulation of mPGES-1 and COX-2 in 
the RA synovium. This phenomenon also applies for two other RA therapeutic 
approaches, TNF blockers and B-cell depletion therapy, making three of the most 
effective RA therapies powerless against the inducible PGE2 pathway [67, 68]. One way 
to further characterize the therapeutic potential of mPGES-1 inhibition would be to 
evaluate the effect of compounds II and III in combination with MTX, TNF blockers 
or B-cell depletion therapy in a relevant model of arthritis i.e. a model in which MTX, 
TNF blockers or B-cell depletion therapy also leave the induction of mPGES-1 and 
COX-2 unaffected. 
 
Alternatively, in paper II we characterized a novel mechanism by which mPGES-1 and 
COX-2 are up-regulated in RASFs and which involves HMGB1. The therapeutic 
potential of HMGB1 has already been evaluated in animal models of arthritis using 
monoclonal antibody therapy. It was shown to reduce both inflammation and tissue 
destruction. It would be important to determine if HMGB1 blocking therapy reduces 
the expression of mPGES-1 and COX-2. Such a finding would make it a candidate for 
a combinatorial approach with MTX, TNF blockers or B-cell depletion therapy. 
 
Compounds II and III described in papers IV and VI are some of the first mPGES-1 
inhibitors with a reported activity in vitro and in vivo on murine mPGES-1. This activity 
is crucial in the study of mPGES-1 as a therapeutic target in the various pathologies 
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presented in section 3. mPGES-1 inhibition has already been investigated in models for 
a number of those diseases, including CIA and EAE, using the mPGES-1 knockout 
mouse. However, as pointed out by the PG profile of air pouch exudates in paper V, 
the partial reduction in PGE2 synthesis achieved by pharmacological inhibition does not 
necessarily have the same impact as the complete reduction achieved by mPGES-1 
gene deletion. It will therefore be very interesting to evaluate the impact of compound 
II and III in disease models where mPGES-1 in implicated including those for which 
the question was already investigated using the mPGES-1 knock out mouse. 
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